[Immunologic and enzymatic markers of acute infantile lymphoblastic leukemias].
Marcos González, Giovanni Traumueller Tamagnini, Jesús F. San Miguel, Lopes Dt, G Mateos, M D Caballero, L Ribeiro, A Lopez Borrasca
Abstract
Marcos González, Giovanni Traumueller Tamagnini, Jesús F. San Miguel, Lopes Dt, G Mateos, M D Caballero, L Ribeiro, A Lopez Borrasca
Abstract
Twenty-one childhood acute lymphoblastic leukemias were characterized immunologically by a series of classic markers--EAET rosette and surface and cytoplasm immunoglobulins--, a panel of 14 monoclonal antibodies --OKla 1, OKT3, 4, 6, 8, 9, 10, 11, cALLA, Leu-1, FMC-7, FMC-8 and 3A-1--and by assessment of terminal deoxynucleotidyl transferase enzyme. Patients were distributed in five immunological subgroups: 1) Unclassifiable/null ALL (la +, TdT+, cALLA-), one patient, 2) common ALL (la+, TdT+, cALLA+) 15 patients, 3) pre-B ALL (la+, TdT+, cALLA+, clg+) one patient, 4) B-LL (la+, TdT-, cALLA-, slg+) 3 patients, 5) T-ALL (TdT+, EAET+, la-, cALLA-), one patient, and the clinical, biological, morphological and cytochemical peculiarities characterizing each immunological variant are discussed.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Twenty-one childhood acute lymphoblastic leukemias were characterized immunologically by a series of classic markers--EAET rosette and surface and cytoplasm immunoglobulins--, a panel of 14 monoclonal antibodies --OKla 1, OKT3, 4, 6, 8, 9, 10, 11, cALLA, Leu-1, FMC-7, FMC-8 and 3A-1--and by assessment of terminal deoxynucleotidyl transferase enzyme. Patients were distributed in five immunological subgroups: 1) Unclassifiable/null ALL (la +, TdT+, cALLA-), one patient, 2) common ALL (la+, TdT+, cALLA+) 15 patients, 3) pre-B ALL (la+, TdT+, cALLA+, clg+) one patient, 4) B-LL (la+, TdT-, cALLA-, slg+) 3 patients, 5) T-ALL (TdT+, EAET+, la-, cALLA-), one patient, and the clinical, biological, morphological and cytochemical peculiarities characterizing each immunological variant are discussed.
Key concepts: Calla, Terminal deoxynucleotidyl transferase, Monoclonal antibody, Medicine, Antibody, Immunology, Immunohistochemistry, TUNEL assay